Displaying 1 - 50 of 69 results
Released Company Title Industry Topic
23 May 2024
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease 20103010 Biotechnology Corporate life
15 May 2024
07:00 CEST
VIVORYON Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 20103010 Biotechnology Corporate life
08 May 2024
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 20103010 Biotechnology General meeting / Board Meeting
24 Apr 2024
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates 20103010 Biotechnology Corporate life
16 Apr 2024
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 20103010 Biotechnology Other subject
15 Mar 2024
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Changes to Board Composition 20103010 Biotechnology Corporate life
04 Mar 2024
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease 20103010 Biotechnology Corporate life
08 Jan 2024
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 20103010 Biotechnology Meetings / events
06 Dec 2023
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress 20103010 Biotechnology Corporate life
28 Nov 2023
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 20103010 Biotechnology Other subject
07 Nov 2023
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference 20103010 Biotechnology Meetings / events
26 Oct 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision 20103010 Biotechnology Other subject
23 Oct 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose 20103010 Biotechnology Other subject
17 Oct 2023
15:32 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders 20103010 Biotechnology Meetings / events
05 Oct 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation 20103010 Biotechnology Other subject
15 Sep 2023
13:57 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board 20103010 Biotechnology General meeting / Board Meeting
07 Sep 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
31 Aug 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023 20103010 Biotechnology Other subject
04 Aug 2023
23:35 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023 20103010 Biotechnology General meeting / Board Meeting
04 Aug 2023
23:30 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer 20103010 Biotechnology Other subject
16 Jul 2023
09:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease 20103010 Biotechnology Corporate life
21 Jun 2023
18:02 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting 20103010 Biotechnology General meeting / Board Meeting
15 Jun 2023
17:49 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces CEO Transition Plan 20103010 Biotechnology Other subject
01 Jun 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences 20103010 Biotechnology Meetings / events
26 May 2023
07:39 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million 20103010 Biotechnology Change in Capital
25 May 2023
17:50 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering 20103010 Biotechnology Other financial transaction
16 May 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
09 May 2023
07:02 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023 20103010 Biotechnology General meeting / Board Meeting
09 May 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023 20103010 Biotechnology Other subject
01 May 2023
10:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting 20103010 Biotechnology Other subject
24 Apr 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences 20103010 Biotechnology Other subject
19 Apr 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
14 Apr 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 20103010 Biotechnology Other subject
28 Mar 2023
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease 20103010 Biotechnology Other subject
21 Feb 2023
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at Upcoming Conferences 20103010 Biotechnology Meetings / events
03 Feb 2023
14:32 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference 20103010 Biotechnology Meetings / events
28 Nov 2022
13:30 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD) 20103010 Biotechnology Meetings / events
23 Nov 2022
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares 20103010 Biotechnology Other subject
22 Nov 2022
07:20 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress 20103010 Biotechnology Other subject
14 Nov 2022
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022 20103010 Biotechnology Other subject
30 Sep 2022
08:47 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress 20103010 Biotechnology Commercial results
30 Sep 2022
08:45 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million 20103010 Biotechnology Change in Capital
26 Sep 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022 20103010 Biotechnology Other subject
31 Jul 2022
18:05 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 20103010 Biotechnology Trends / Analyses
31 Jul 2022
18:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O 20103010 Biotechnology Trends / Analyses
23 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD 20103010 Biotechnology Trends / Analyses
22 Jun 2022
19:13 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022 20103010 Biotechnology General meeting / Board Meeting
15 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress 20103010 Biotechnology Commercial results
08 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022 20103010 Biotechnology Other subject
11 May 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 20103010 Biotechnology General meeting / Board Meeting